Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage Therapy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background Concerns about the rise in antimicrobial resistance have led to renewed interest in phage therapy worldwide, but perceptions among relevant medical professionals in Korea remain largely unknown. Materials and Methods We conducted a semi-quantitative online survey to evaluate the Korean infectious disease specialists' perception of phage therapy. Results We sent out the link to the questionnaire to 380 subjects and received 91 replies, with 90/91 respondents identifying as Korean infectious diseases specialists or trainees. Ten out of 91 (11.0%) respondents scored themselves as well-informed about phage therapy. The majority (93.4%) of respondents would consider using phage therapy if the safety of the phage formulation is guaranteed, and 80% of respondents would consider participating in clinical trials with phage therapy given adequate support. The biggest concern was uncertainty about safety (73.6%) and efficacy (65.9%). Acinetobacter baumannii was ranked as a high priority for phage therapy research, as were bone and joint infections. Conclusion Korean infectious diseases specialists are receptive to phage therapy, but a better understanding of safety, efficacy and clinical trials are warranted to progress phage therapy within the Korean healthcare system.
Abstract
Background Concerns about the rise in antimicrobial resistance have led to renewed interest in phage therapy worldwide, but perceptions among relevant medical professionals in Korea remain largely unknown. Materials and Methods We conducted a semi-quantitative online survey to evaluate the Korean infectious disease specialists' perception of phage therapy. Results We sent out the link to the questionnaire to 380 subjects and received 91 replies, with 90/91 respondents identifying as Korean infectious diseases specialists or trainees. Ten out of 91 (11.0%) respondents scored themselves as well-informed about phage therapy. The majority (93.4%) of respondents would consider using phage therapy if the safety of the phage formulation is guaranteed, and 80% of respondents would consider participating in clinical trials with phage therapy given adequate support. The biggest concern was uncertainty about safety (73.6%) and efficacy (65.9%). Acinetobacter baumannii was ranked as a high priority for phage therapy research, as were bone and joint infections. Conclusion Korean infectious diseases specialists are receptive to phage therapy, but a better understanding of safety, efficacy and clinical trials are warranted to progress phage therapy within the Korean healthcare system.
참고문헌 (39)
- Hatfull GF, "Phage therapy for antibiotic-resistant bacterial infections", Annu Rev Med, 73, pp.197~211 (2022)
- Petrovic Fabijan A, "Phage therapy for severe bacterial infections : a narrative review", Med J Aust, 212, pp.279~285 (2020)
- Tackling drug-resistant infections globally: final reportand recommendations, "O’Neill J", Review on Antimicrobial Resistance, ~ (2016)
- Uyttebroek S, "Safety and efficacy of phage therapy in difficult-to-treat infections : a systematic review", Lancet Infect Dis, 22, pp.e208~e220 (2022)
- El Haddad L, "A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans", Clin Infect Dis, 69, pp.167~178 (2019)
- Suh GA, "Considerations for the use of phage therapy in clinical practice", Antimicrob Agents Chemother, 66, pp.e0207121~ (2022)
- Dedrick RM, "Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus", Nat Med, 25, pp.730~733 (2019)
- Dedrick RM, "Phage therapy of Mycobacterium infections : compassionate use of phages in 20 patients with drug-resistant mycobacterial disease", Clin Infect Dis, 76, pp.103~112 (2023)
- Gilbey T, "Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus", Med J Aust, 211, pp.142~143 (2019)
- Khatami A, "Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child", EMBO Mol Med, 13, pp.e13936~ (2021)
- Maddocks S, "Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa", Am J Respir Crit Care Med, 200, pp.1179~1181 (2019)
- Petrovic Fabijan A, "Safety of bacteriophage therapy in severe Staphylococcus aureus infection", Nat Microbiol, 5, pp.465~472 (2020)
- Schooley RT, "Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection", Antimicrob Agents Chemother, 61, pp.e00954-17~ (2017)
- "ClinicalTrials.gov. Phage therapy for the treatment of urinary tract infection"[URL]
- "ClinicalTrials.gov. A phase 1b/2 trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa"[URL]
- Kim B, "Professional status of infectious disease specialists in Korea : a nationwide survey", J Korean Med Sci, 37, pp.e320~ (2022)
- "Please participate in our 'Perception of phage therapy among Australian prescribers' survey"[URL]
- Bretaudeau L, "Good manufacturing practice(GMP)compliance for phage therapy medicinal products", Front Microbiol, 11, pp.1161~ (2020)
- Ryu S, "The new Korean action plan for containment of antimicrobial resistance", J Glob Antimicrob Resist, 8, pp.70~73 (2017)
- "Republic of Korea: Second national action plan on antimicrobial resistance 2021-2025 (Korean)"[URL]
- Jault P, "Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa(PhagoBurn) : a randomised, controlled, double-blind phase 1", 2 trial, 2019, pp.19, 35~45
- Liu D, "The safety and toxicity of phage therapy : a review of animal and clinical studies", Viruses, 13, pp.1268~ (2021)
- Stacey HJ, "The safety and efficacy of phage therapy : a systematic review of clinical and safety trials", Antibiotics(Basel), 11, pp.1340~ (2022)
- Navarro F, "Phages in the human body", Front Microbiol, 8, pp.566~ (2017)
- "Study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 in subjects with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection"[URL]
- "A phase 1b/2 trial of the safety and microbiological activity of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa"[URL]
- "gov/show/NCT05369104"[URL]
- "Study evaluating safety, tolerability, and efficacy of intravenous AP-SA02 in subjects with S. aureus bacteremia"[URL]
- De Oliveira DMP, "Antimicrobial resistance in ESKAPE pathogens", Clin Microbiol Rev, 33, pp.e00181-19~ (2020)
- Kim D, "Major bloodstream infection-causing bacterial pathogens and their antimicrobial resistance in South Korea, 2017-2019 : phase I report from Kor-GLASS", Front Microbiol, 12, pp.799084~ (2022)
- Kim YA, "Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea", Korean J Intern Med, 33, pp.247~255 (2018)
- Song KH, "Clinical and economic burden of bacteremia due to multidrug-resistant organisms in Korea : a prospective case control study", J Glob Antimicrob Resist, 31, pp.379~385 (2022)
- Kang CI, "Antimicrobial resistance in Asia : current epidemiology and clinical implications", Infect Chemother, 45, pp.22~31 (2013)
- Cheon S, "Controlling endemic multidrug-resistant Acinetobacter baumannii in intensive care units using antimicrobial stewardship and infection control", Korean J Intern Med, 31, pp.367~374 (2016)
- Kim CJ, "Socioeconomic burden of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Korea", Sci Rep, 12, pp.13934~ (2022)
- Rao S, "Critically ill patient with multidrug-resistant Acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy", Antimicrob Agents Chemother, 66, pp.e0082421~ (2022)
- Pirnay JP, "The magistral phage", Viruses, 10, pp.64~ (2018)
- Khatami A, "Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients(STAMP study) : protocol for an open-label, single-arm trial", BMJ Open, 12, pp.e065401~ (2022)